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There is an increasing interest by doctors and patients in extracorporeal shock wave therapy (ESWT) for chronic
plantar fasciopathy (PF), particularly in second generation radial extracorporeal shock wave therapy (RSWT). The
present review aims at serving this interest by providing a comprehensive overview on physical and medical
definitions of shock waves and a detailed assessment of the quality and significance of the randomized clinical trials
published on ESWT and RSWT as it is used to treat chronic PF. Both ESWT and RSWT are safe, effective, and
technically easy treatments for chronic PF. The main advantages of RSWT over ESWT are the lack of need for any
anesthesia during the treatment and the demonstrated long-term treatment success (demonstrated at both 6 and
12 months after the first treatment using RSWT, compared to follow-up intervals of no more than 12 weeks after
the first treatment using ESWT). In recent years, a greater understanding of the clinical outcomes in ESWT and
RSWT for chronic PF has arisen in relationship not only in the design of studies, but also in procedure, energy level,
and shock wave propagation. Either procedure should be considered for patients 18 years of age or older with
chronic PF prior to surgical intervention.
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Plantar fasciitis (PF), the most common cause of heel
pain, accounts for approximately 11% to 15% of foot
symptoms presenting to physicians. In the United States,
more than 2 million individuals are treated for PF on an
annual basis [1-3]. The term ‘plantar fasciitis’ implies an
inflammatory condition by the suffix ‘itis’. However, various
lines of evidence indicate that this disorder is better classi-
fied as ‘fasciosis’ or ‘fasciopathy’, as heel pain is associated
with degenerative changes in the fascia and atrophy of the
abductor minimi muscle [1]. When chronic, PF is not an
inflammatory condition [1].
The etiology, pathogenesis, associated risk factors, and
general treatment strategies for PF have been documented
in other comprehensive reviews [1-6]. The condition is
usually diagnosed clinically based on the history of morning
heel pain made worse with ambulation on hard surfaces
and by the physical findings of pain over the medial aspect* Correspondence: christoph_schmitz@med.uni-muenchen.de
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reproduction in any medium, provided the orof the plantar fascia. PF has a bimodal distribution,
afflicting both athletes and the sedentary. Imaging studies,
while generally not needed, can be helpful for ruling out
other causes of heel pain or to establish the diagnosis of
PF when in doubt.
Initial treatment is non-operative and consists of relative
rest, physical therapy, stretching, exercises, shoe inserts/
orthotics, night splints, non-steroidal anti-inflammatory
drugs, and local corticosteroid injections. Patients not
responding to conservative treatment for 4 to 6 months
(between 10% and 20% of all patients) are candidates for
more aggressive treatment such as extracorporeal shock
wave therapy (ESWT) and surgery [1,2].
The safety and efficacy of ESWT for chronic PF has been
assessed in a variety of randomized clinical trials (RCTs).
Rompe et al. [5] have already reviewed the results of using
focused shock wave therapy to treat chronic PF. Since then,
five RCTs have assessed the safety and efficacy of radial
extracorporeal shock wave therapy (RSWT) for chronic PF
[7-11]. Recently, Dizon et al. [12] reviewed the results of
using both ESWTand RSWT for chronic PF [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physical and medical definitions of shock waves, as well
as a detailed assessment of the quality and significance of
the recently published RCTs on both ESWT and RSWT
for chronic PF.Shock waves
Physical definition of shock waves
A shock wave is an acoustic pressure wave that is pro-
duced in any elastic medium such as air, water, or even a
solid substance [13,14]. Shock waves differ from sound
waves in that the wave front, where compression takes
place, is a region of sudden change in stress and density
[13,14]. Because of this, shock waves propagate in a
manner different from that of the ordinary acoustic
waves. In particular, shock waves travel faster than
sound, and their speed increases as the amplitude is
raised; however, the intensity of a shock wave also de-
creases faster than does that of a sound wave because
some of the energy of the shock wave is expended to
heat the medium in which it travels [13,14].
Accordingly, shock waves are characterized by (1) a
high positive peak pressure (P+), sometimes more than
100 MPa but more often approximately 50 to 80 MPa,
(2) a fast initial rise in pressure (Tr) during a period
of less than 10 ns, (3) a low tensile amplitude (P−,
up to 10 MPa), (4) a short life cycle (I) of approxi-
mately 10 μs, and (5) a broad frequency spectrum,
typically in the range of 16 Hz to 20 MHz [15,16].
The measured shock wave rise time is in the 30-ns
range when determined by limited time resolution of
the pressure recording hydrophone [15,16]. The posi-
tive pressure amplitude is followed by a diffraction-
induced tensile wave of a few microseconds duration
(Figure 1).Figure 1 Pressure as a function of time of a shock wave. P+, positive p
interval during which the positive pressure changes from 10% of P+ to 90%
shock wave; I, time interval to calculate the total energy of the shock waveMedical definitions of shock waves
Extracorporeal shock wave lithotripsy (ESWL) is widely
used for stone management in urology. The pressure waves
applied in stone management fulfill the characteristics set
out by the physical definition of shock waves provided
above [17]. The fast initial rise time in pressure and the
high positive pressure causes a pressure gradient within the
renal calculi that, when of sufficient energy, can fragment
the calculi [18].
ESWT and RSWT are by-products of lithotriptor tech-
nology. They were introduced into the treatment for
various diseases of the musculoskeletal system, such as
PF, Achilles tendinopathy, medial tibial stress syndrome,
greater trochanteric pain syndrome, lateral and medial
epicondylitis, and calcifying tendonitis of the shoulder
since the late 1980s [19].
Shock waves have both a direct and indirect effect on
treated tissues. The direct effect is the result of the energy
of the shock wave being transferred to the targeted tissues.
The indirect effect is the result of the production of cavita-
tion bubbles in the treated tissue [13,14]. Both the direct
and indirect effects produce a biological response in the
treated tissues.
Shock wave generators
In the United States, the following ESWT/RSWT devices
obtained premarket approval (PMA) by the Food and Drug
Administration (FDA) as class III orthopedic lithotripsy
devices and were reclassified as class III Generators, Shock
Wave, For Pain Relief (Product Code NBN) in the Spring
2009: (1) Ossatron (HealthTronics, Inc., Marietta, GA,
USA), PMA # P990086 issued on October 12, 2000 to
treat chronic heel pain; (2) Epos Ultra (Dornier Medical
Systems, Inc., Kennesaw, GA, USA), PMA # P000048
issued on January 15, 2002 for the treatment of chronic
plantar fasciitis for patients with symptoms of plantareak pressure; P−, negative peak pressure; Tr, rise time (i.e., the time
of P+); I+, time interval used to calculate the positive energy of the
.
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conservative therapy; (3) Sonocur Basic (Siemens Medical
Solutions, Inc., Iselin, NJ, USA), PMA # P010039 issued
on July 19, 2002 for the treatment for pain due to tennis
elbow; (4) Orthospec Extracorporeal Shock Wave Therapy
(Medispec, Ltd; Germantown, MD, USA), PMA # P040026
issued on April 1, 2005 for the treatment of proximal plan-
tar fasciitis with or without heel spur in patients 18 years of
age or older; (5) Orbasone Pain Relief System (Orthometrix,
Inc., White Plains, NY, USA), PMA # P040039 issued on
August 10, 2005 to relieve heel pain (proximal plantar
fasciitis); and (6) Swiss DolorClast (EMS Electro Medical
Systems; Dallas, TX, USA), PMA # P050004 issued on
May 8, 2007 to treat heel pain associated with chronic
proximal plantar fasciitis [20].
The Ossatron, Epos Ultra, Sonocur Basic, and Orbasone
devices share the following technical key characteristics
of ESWL devices used for stone management: (1) electro-
hydraulic (OssaTron, Orbasone) or electromagnetic (Epos
Ultra, Sonocur) generation of pressure waves and (2) gen-
eration of focused pressure waves. The Orthospec device
also uses electrohydraulic spark gap technology to generate
pressure waves. The Swiss DolorClast generates radial
pressure waves ballistically, i.e., by accelerating a bullet to
strike an applicator, which transforms the kinetic energy of
the bullet into a radially expanding pressure wave [8,21].
It should be noted that studies by Chitnis and Cleveland
[22] and Cleveland et al. [23] showed that the Swiss
DolorClast does not generate pressure waves that fulfill
the characteristics set out by the physical definition of
shock waves provided above. Specifically, the rise time of
the pressure waves generated by the Swiss DolorClast was
reported as 600 [22] or 800 ns [23], respectively. This
rise time is approximately 90 times longer than would
be expected for a shock wave [23]. Furthermore, the
maximum peak positive pressure of the Swiss DolorClast
was reported as 5 [22] or 7 MPa [23], respectively.
Accordingly, the question has been raised whether the
pressure waves generated with the Ossatron, Epos Ultra,
Sonocur Basic, Orbasone, and Orthospec devices fulfill
the characteristics set out by the physical definition of
shock waves provided above. This is addressed in the
Appendix.
Treatment of chronic plantar fasciopathy with focused
shock waves
Rompe et al. [5] assessed the quality of all RCTs on
focused ESWT for chronic PF that were published in the
international peer-reviewed literature until then. To this
end, the authors applied evaluation criteria established
by Chalmers et al. [24], consisting of two evaluation
forms that include 29 individually scored items, allowing
a maximum score of 100. Besides this, Rompe et al. [5]
used evaluation criteria established by Jadad et al. [25],attributing to each RCT a quality score out of a maximum
of six points, addressing the following questions: (1) was
the generation of randomization sequence described? (2)
was the method of allocation concealment described? (3)
was an intention to treat analysis used? (4) what number
of patients was lost to follow up? (5) was the outcome
assessment blind? and (6) was the patient blind to treatment
allocation?
This assessment resulted in the following quality scores
(see also Table 1): (1) Haake et al. [26], 90 (according to
Chalmers et al. [24])/6 (according to Jadad et al. [25]); (2)
Kudo et al. [27], 88/6; (3) Malay et al. [28], 84/6; and (4)
Buchbinder et al. [29], 82/4. All other RCTs had lower
scores and were not classified as good by Rompe et al. [5];
the same holds true for the only RCT on focused ESWT
for chronic PF published since then by Gollwitzer et al.
[30]. Dizon et al. [12] assessed the same studies using the
so-called physiotherapy evidence database (PEDro) scale
[31] and ranked them as follows (maximum scale = 11):
(1) Kudo et al. [27], Malay et al. [28], and Buchbinder et al.
[29], 10; (2) Gollwitzer et al. [30], 9; and (3) Haake et al.
[26], 8. Because of the difference between the assessments
by Rompe et al. [5] and Dizon et al. [12] and considering
that Rompe et al.’s [5] assessment criteria are more sensi-
tive than the assessment criteria used by Dizon et al. [12],
the latter was no longer considered in this review.
Interestingly, Kudo et al. [27] and Malay et al. [28] found
statistically significantly (p < 0.05) better outcomes for the
patients treated with ESWT than the patients treated with
placebo whereas Haake et al. [26] and Buchbinder et al.
[29] did not. At first glance, this may be confusing as
Haake et al. [26], Kudo et al. [27], and Buchbinder et al.
[29] used the same ESWT device (namely, the Epos Ultra).
As outlined in the following, however, this discrepancy
can be explained by methodological differences between
these studies, going beyond the generalized quality criteria
for RCTs established by Chalmers et al. [24], Jadad et al.
[25], or the PEDro scale [31]. Specifically, application of
placebo treatment, patient blinding, and the use of local
anesthesia in RCTs with ESWT for chronic PF needs to be
addressed (Table 1).
Application of placebo treatment and patient blinding
The application of placebo treatment in RCTs with ESWT
for chronic PF can be achieved in three different ways: (1)
treating patients in the placebo group in exactly the same
manner as patients in the active group but modifying the
shock wave device so that it does not deliver shock waves.
This was done in the study by Malay et al. [28] using a
foam-insulated contact membrane placed on the applicator
that absorbed the shock waves and inhibited transmission
of most of the energy but looked identical to an unlined
(non-insulated) contact membrane placed on the applicator
when treating patients in the active group. (2) Treating
Table 1 RCTs on ESWT for chronic PF classified as good by Rompe et al. [5]
Study Outcome Chalmers scorec Jadad scored Placebo treatment L.A. Patients
Haake et al. [26] −a 90 6 e +h j
Kudo et al. [27] +b 88 6 e −i k
Malay et al. [28] +b 84 6 f − k
Buchbinder et al. [29] −a 82 4 g − j
aLack of statistically significantly (p < 0.05) better outcome for the patients treated with ESWT than the patients treated with placebo; bstatistically significantly (p
< 0.05) better outcome for the patients treated with ESWT than the patients treated with placebo; cquality score according to Chalmers et al. [24]; dquality score
according to Jadad et al. [25]; etreatment of patients in the placebo group in exactly the same manner as patients in the active group but placing a foam-
insulated or air-filled membrane between the applicator of the shock wave device and the patient’s skin that reflects the shock waves; ftreatment of patients in
the placebo group in exactly the same manner as patients in the active group but modifying the shock wave device so that it does not deliver shock waves;
gtreatment of patients in the placebo group with only a small number of shock waves at low energy settings; hlocal anesthesia; imedial calcaneal nerve block
anesthesia; jpatients with symptoms present for less or more than 6 months who have or have not previously failed pharmacologic (analgesic, anti-inflammatory,
or other) and non-pharmacologic treatment modalities for the relief of heel pain; konly patients with symptoms present for more than 6 months who have
previously failed pharmacologic (analgesic, anti-inflammatory, or other) and non-pharmacologic treatment modalities for relief of heel pain.
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as patients in the active group but placing a foam-insulated
or air-filled membrane between the applicator of the shock
wave device and the patient’s skin that reflects the shock
waves. This was done in the studies by Haake et al. [26]
and Kudo et al. [27]. (3) Treating patients in the placebo
group with only a small number of shock waves at low en-
ergy settings. This was applied in the study by Buchbinder
et al. [29]. Specifically, Buchbinder et al. [29] treated
patients in the placebo group with only 100 impulses with
energy flux density (EFD) of 0.02 mJ/mm2 per treatment
session, but patients in the active group were treated with
2,000 or 2,500 impulses with EDF varying between 0.02
and 0.33 mJ/mm2 per treatment session.
From a methodological point of view, the first option
provides the best patient blinding and is the only one in
which unblinding of the patients by the ESW therapist
can be excluded (provided that the preparation of the
device is performed by an independent person, or the
ESW therapist is provided with coded ‘active’ and ‘placebo’
handpieces; note that in the study by Malay et al. [28], the
ESW therapists were not blinded). The second and third
options do not keep the ESW therapists ‘unaware’ of the
assigned treatment, opening the possibility that they could
be influenced by that knowledge. This requires a strict,
standardized way of interaction between the ESW therapist
and the patients, irrespective of the treatment allocation
(as mentioned in the study by Buchbinder et al. [29]).
Moreover, the third option inherits the highest chance of
patients’ unblinding because patients could conclude from
the knowledge that is available freely that they were not in
the active group. For example, treatment of chronic PF
with focused ESWT devices can last for more than 10 min
(because the frequency to apply the shock waves using
these devices is limited to a few Hz) and can be very
painful for the patients if applied without anesthesia
(as performed in the study by Buchbinder et al. [29]).
However, in the study by Buchbinder et al. [29], the pla-
cebo treatment lasted less than 2 min (only 100 impulsesapplied at a frequency of 1 Hz), whereas the active treat-
ment lasted more than 10 min (2,000 or 2,500 impulses
applied at frequencies that were gradually increased to
4 Hz). Thus, in the study by Buchbinder et al. [29], the pa-
tients in the placebo group received a painless treatment
during a short treatment time, whereas the patients in
the active group received a painful treatment during a
substantially longer treatment time (note that the active
treatment was actually gradually increased through to the
highest tolerable level of pain for each participant in this
study).
Accordingly, the quality of patient blinding (and thus
allocation concealment) in the aforementioned studies
can be ranked as follows: Malay et al. [28] > Haake et al.
[26] = Kudo et al. [27] > Buchbinder et al. [29].
Use of local anesthesia
The pain associated with the application of focused shock
waves and the need for patient blinding in RCTs testing
painful treatment modalities imply that RCTs with ESWT
for chronic PF should be performed under local anesthesia
(as done by Haake et al. [26]) or nerve block anesthesia
(as done by Kudo et al. [27]). However, the application of
local anesthesia might contribute to negative outcome of
such studies, as demonstrated by Rompe et al. [32]. The
molecular mechanisms underlying this phenomenon are
not yet fully understood, but substantial evidence points to
a central role of the peripheral nervous system in mediating
molecular and cellular effects of shock waves applied to
the musculoskeletal system [33-35]. These effects could
be blocked by local anesthesia, as demonstrated in a
recent study by Klonschinski et al. [36]. Thus, it is now
generally recommended to apply shock waves without
local anesthesia to the musculoskeletal system.
Kudo et al. [27] did not use local anesthesia, but a
medial calcaneal nerve block anesthesia. The authors
applied a total of 3,800 impulses in a single session with
an average EFD of 0.34 mJ/mm2. In contrast, Malay et al.
[28] did not use any anesthesia. These authors applied a
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approximately 540 impulses for each of the seven energy
levels of the device used (Orthospec) (resulting in an
average EFD of 0.2 mJ/mm2). Buchbinder et al. [29] did not
use any anesthesia either. The average EFD per impulse in
this study (2,000 or 2,500 impulses per treatment session,
three treatment sessions, average total EFD = 1,406.73 mJ/
mm2) was approximately 0.21 mJ/mm2.
Accordingly, with respect to the use of local anesthesia,
the aforementioned studies can be ranked as follows:
Malay et al. [28] = Buchbinder et al. [29] > Kudo et al.
[27] > Haake et al. [26].
Significance of published, randomized clinical trials on
focused shock wave treatment for chronic plantar
fasciopathy
Considering the aforementioned methodological issues,
the RCTs using focused ESWT for chronic PF that were
evaluated as good by Rompe et al. [5] can be assessed as
follows.
Buchbinder et al. [29] included a total of n = 166
patients with symptoms of PF for at least 6 weeks (range 8
to 980 weeks) into their study. Patients in the active group
received three sessions of ESWT at weekly intervals,
with 2,000 or 2,500 impulses with EFD varying between
0.02 mJ/mm2 and 0.33 mJ/mm2 per treatment session.
Patients in the placebo group received only 100 impulses
with EFD = 0.02 mJ/mm2 per treatment session.
At 6 and 12 weeks, there were significant improvements
in overall pain in both the active group and the placebo
group. Similar improvements in both groups were also
observed for morning and activity pain, walking ability,
and other end points. However, there were no statistically
significant (p < 0.05) differences in the degree of improve-
ment between the groups for any measured outcomes.
It is important to recognize that Buchbinder et al. [29]
did not treat chronic PF according to the classic definition
of ‘chronic’ (i.e., patients not responding to conservative
treatment for 6 months). Rather, Buchbinder et al. [29]
investigated mixed groups of patients suffering from either
acute (as short as 8 weeks) or chronic PF. Furthermore, it
appears that not all of the patients enrolled by Buchbinder
et al. [29] received conservative care before inclusion in
the study. For example, only 54% (90/166) of the patients
were treated with orthotics before ESWT, only 31%
(51/166) received cortisone injections before ESWT,
and only 13% (21/166) were treated with physiotherapy
before ESWT.
Haake et al. [26] treated a total of n = 272 patients
with three sessions of 4,000 focused shock waves with
EFD = 0.08 mJ/mm2 under local anesthesia or placebo at
weekly intervals. After 12 weeks, the success rate was
34% in the ESWT group and 30% in the placebo group;
the difference was not statistically significant (p > 0.05).This study was criticized because fewer than half of
the enrolled patients received minimal conservative care
such as stretching exercises, casting, or night splinting
before inclusion in the study (similar to the situation in
the study by Buchbinder et al. [29]) [37]. Furthermore,
the lack of treatment success in the ESWT group in the
study by Haake et al. [26] can be explained by the fact
that these authors applied shock waves under local
anesthesia.
Kudo et al. [27] in a trial of 114 patients with chronic
PF, recalcitrant to conservative therapies for at least six
months, achieved treatment success by applying focused
shock waves (single sessions of 3,800 impulses with
EFD = 0.34 mJ/mm2) or placebo treatment under medial
calcaneal nerve block anesthesia. Good or excellent out-
come was reported by 43% of the patients treated with
focused shock waves at 12-weeks follow-up and by 30% of
the placebo-treated patients (p < 0.05). Kudo et al. [27] did
not report the results at longer than 12 weeks after the
treatment.
Malay et al. [28] included a total of n = 172 patients
with symptoms present for more than 6 months into
their study. Patients must have previously failed two
pharmacologic (analgesic, anti-inflammatory, or other)
and two non-pharmacologic treatment modalities for the
relief of heel pain to be included in the study. Patients
were treated with a single session of 3,800 shock waves or
placebo, without local anesthesia. The energy flux density
of the applied shock waves was continuously increased
from 0.08 mJ/mm2 (lowest energy level of the used device)
to 0.33 mJ/mm2 (highest energy level of the used device).
At 12 weeks, 43% of the patients treated with shock waves
and 20% of the patients treated with placebo reported a
50% decrease of pain from baseline (statistically significant,
p < 0.05). As with Kudo et al.’s [27] trial, Malay et al. [28]
did not follow up with the patients longer than 12 weeks
after the treatment.
In summary, the lack of treatment success in the
studies by Buchbinder et al. [29] and Haake et al. [26]
using focused ESWT for PF can be explained by serious
methodological shortcomings in the corresponding studies.
In contrast, the studies by Kudo et al. [27] and Malay et al.
[28] demonstrated that chronic PF can be treated success-
fully with focused shock waves. Furthermore, the study
by Malay et al. [28] showed that treatment success can
be achieved without any anesthesia. However, long-term
(>12 weeks) treatment success has not been demonstrated
in either of these trials.
Treatment of chronic plantar fasciopathy with radial
shock waves
Five RCTs have assessed the safety and efficacy of RSWT
for chronic PF [7-11]. Two of these studies (Gerdesmeyer
et al. [8] and Ibrahim et al. [11]) fulfilled all evaluation
Figure 2 Shadowgraph images of radial (A) and focused (B)
shock waves (details are provided in the main text).
Schmitz et al. Journal of Orthopaedic Surgery and Research 2013, 8:31 Page 6 of 11
http://www.josr-online.com/content/8/1/31criteria established by Chalmers et al. [24] and Jadad et al.
[25] outlined above. Using the PEDro scale [31], Dizon
et al. [12] ranked these studies as follows: (1) Gerdesmeyer
et al. [8] and Ibrahim et al. [11], 10; (2) Chow and Cheing
[7], 9; and (3) Greve et al. [10], 7. The study by Marks et al.
[9] was not considered by Dizon et al. [12]. Furthermore,
according to Dizon et al. [12], the therapists were not
blinded in the study by Gerdesmeyer et al. [8]. However,
this is not correct. Gerdesmeyer et al.’s [8] study was a
double-blind, randomized, placebo-controlled trial and,
thus, should have received a PEDro scale score of 11 in
Dizon et al.’s [12] assessment.
Radial shock waves can be delivered to the tissue
without local or nerve block anesthesia, and no form of
anesthesia was used in the aforementioned trials. In
general, radial extracorporeal shock wave therapy is
better tolerated than focused SWT because radial shock
waves have their point of highest pressure and highest
energy flux density at the tip of the applicator and, thus,
outside the tissue. In contrast, focused shock waves have
their point of highest pressure and highest energy flux
density at the center of their focus which is positioned
within the treated tissue. This is demonstrated in Figure 2
showing shadowgraph images of radial and focused shock
waves used for the treatment of the musculoskeletal
system. Shadowgraph imaging is a visual process that is
used to photograph the flow of fluids of varying density.
Figure 2A shows radial shock waves generated with the
Swiss DolorClast. Note the semicircular wave front and
the field of cavitation bubbles surrounded by secondary
shock waves above the applicator. The secondary shock
waves are produced by rapid collapse of the cavitation
bubbles (this process is named inertial cavitation). The
cavitation is consequent to the negative phase of the wave
propagation. The cavitation field produced with the Swiss
DolorClast (15-mm applicator, device operated at 4 bar)
has a size of approximately 15 × 20 mm (width × height).
The hydrophone is used to trigger the flash and the
camera. Figure 2B shows shock waves generated with a
focused shock wave device, Swiss Piezoclast (Electro
Medical Systems; the Swiss Piezoclast is currently not
FDA approved). Note the convergent waves and the
center of the shock wave focus at a height of 4.5 cm
above the applicator. Cavitation bubbles appear near the
center of the shock wave focus. The picture was generated
by mounting five shadowgraph images taken each at 12 μs
apart into one figure. The device was operated so that the
shock waves had a rise time of 79 ns and a positive peak
pressure of 82.8 MPa. Figure 2C shows the cavitation field
of the Swiss Piezoclast surrounded by secondary shock
waves, observed at 31.6 μs after forming the center of the
shock wave focus. The cavitation field has an elliptic shape
with equatorial diameter of approximately 2 cm and polar
diameter of approximately 5 cm. Note that the so-called5-MPa focus (i.e., the region in which the positive pressure
exceeds 5 MPa during the positive phase of the wave
propagation) of the shock waves generated with the Swiss
Piezoclast has an equatorial diameter of 20.8 mm, which
equals the equatorial diameter of the cavitation field caused
by the shock waves generated with the Swiss Piezoclast. It
is of note that the size of the cavitation field depends on
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The images shown here were taken in non-degassed water.
In contrast, Chitnis and Cleveland [22] investigated the
cavitation fields of the Ossatron and Swiss DolorClast
devices in degassed water and obtained the following
results: Ossatron, 10 × 40 mm (width × height) and Swiss
DolorClast, 3 × 3 mm (i.e., five times smaller in width and
height as demonstrated here). Assuming linear relationships
between the results of Chitnis and Cleveland [22] and
the findings presented here, one would expect that the
cavitation field of the Ossatron device has an equatorial
diameter of approximately 50 mm when evaluated in
non-degassed water. Interestingly, the 5-MPa focus of
the shock waves generated with the Ossatron device has an
equatorial diameter of 64 mm, which equals the equatorial
diameter of the assumed cavitation field caused by the
shock waves generated with this device in non-degassed
water.
Thus, radial shock waves of a certain energy flux density
are generally less painful for and, thus, better tolerated
by the patient than the focused shock waves of the same
energy flux density.
Gerdesmeyer et al. [8] demonstrated safety and effi-
cacy of RSWT with the Swiss DolorClast for chronic PF
in a prospective, randomized, double-blinded, placebo-
controlled international multicenter study. The authors
included a total of n = 245 patients with chronic PF into
their study. Inclusion criteria comprised (among others) a
history of at least 6 months of chronic plantar painful heel
syndrome that proved resistant to non-surgical treatment.
Gerdesmeyer et al. [8] administered RSWT or placebo
treatment in three sessions, each at 2 weeks (±4 days)
apart (2,000 impulses per session, EFD = 0.16 mJ/mm2,
eight impulses per second) and evaluated the treatment
outcome 12 weeks and 12 months after the first session.
The authors found a statistically significant (p < 0.05)
difference in the reduction of the mean visual analog
scale (VAS) composite score between the patients treated
with RSWT (−56.0% ± 39.3%) and the placebo-treated
patients (−44.1% ± 41.8%) at 12 weeks and even more
pronounced superiority of RSWT (−61.9% ± 43.6%) over
placebo (−46.5% ± 45.5%) at 12 months.
Ibrahim et al. [11] tested (in a prospective, randomized,
double-blinded, placebo-controlled study) the hypothesis
that treatment of chronic PF with two RSWT sessions
1 week apart does result in profound pain relief compared
to placebo treatment 4 weeks after the first RSWT treat-
ment, lasting for at least 6 months. To test this hypothesis,
the authors randomly assigned a total of n = 50 patients
with unilateral, chronic PF to either RSWT (n = 25) or
placebo treatment (n = 25). Inclusion and exclusion criteria
were almost identical to those applied by Gerdesmeyer
et al. [8]. RSWT was applied in two sessions 1 week apart
(2,000 impulses with EFD = 0.16 mJ/mm2 per session).Placebo treatment was performed with a clasp on the
heel. End points were changes in the VAS score and the
modified Roles and Maudsley (RM) score from baseline to
4-, 12-, and 24-week follow-up. Ibrahim et al. [11] found
the mean VAS scores reduced after RSWT from 8.52 ±
0.34 (mean ± SEM) at baseline to 0.64 ± 1.52 at 4 weeks,
1.08 ± 0.28 at 12 weeks, and 0.52 ± 0.14 at 24 weeks from
baseline. Similar changes were found for mean RM scores
after RSWT but were not observed after placebo treatment.
Statistical analysis demonstrated that RSWT resulted in
significantly reduced mean VAS scores and mean RM
scores at all follow-up intervals compared to placebo
treatment (each with p < 0.001). No serious adverse events
of RSWT were observed. Ibrahim et al. [11] concluded
that RSWT is efficient in the treatment for chronic PF
even when only two sessions with 2,000 impulses each are
performed 1 week apart.
To investigate the dose-effect relationship of RSWT to
treatment success, Chow and Cheing [7] randomly assigned
a total of n = 57 patients with chronic PF for at least
3 months to three groups. Patients in group A (n = 19, 17
patients completed the trial) received three sessions of
RSWT each 1 week apart (1,000 impulses per session,
EFD = 0.11 mJ/mm2, three impulses per second). Patients
in group B (n = 19, 18 patients completed the trial) were
treated in the same manner but with increasing energy
flux densities (first week, EFD = 0.12 mJ/mm2; second week,
EFD = 0.15 mJ/mm2; third week, EFD = 0.17 mJ/mm2).
Patients in group C served as control (n = 19, 14 patients
completed the trial; three sessions of RSWT each 1 week
apart, 30 impulses per session, EFD = 0.03 mJ/mm2, three
impulses per second). Six weeks after the first RSWT
session, patients in groups A and B showed (among other
variables) statistically significant (p < 0.05) reductions in
mean VAS scores by 37% (group A) and 83% (group B),
respectively, compared to the baseline. By contrast, pa-
tients in group C showed no changes in mean VAS scores
compared to the baseline. The results of the patients in
group B of the study by Chow and Cheing [7] were
consistent with the results reported by Gerdesmeyer et al.
[8] and Ibrahim et al. [11], indicating that the energy flux
density of the applied radial shock waves must exceed a
certain level in order to cause a therapeutic effect.
Other trials investigating the use of RSWT to treat
chronic PF have yielded negative outcomes. Marks et al.
[9] enrolled 25 adult patients with chronic PF in their study.
The authors randomly assigned 16 patients to RSWT (three
sessions each 3 days apart, 500 impulses in the first
session and 2,000 impulses in the second and third session,
respectively; EFD = 0.16 mJ/mm2, frequency of the impulses
not provided). Another nine patients were placebo treated
(i.e., in the same manner as the patients subjected to
RSWT but with the energy flux density of the radial
shock waves reduced to almost zero). Of the patients,
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(4/9) of the patients treated with placebo reported
(compared to baseline) a reduction in the VAS score
greater than 50%, 6 months after the first session (defined
as treatment success by the authors). This difference was
not statistically significant (p > 0.05). However, the total
mean VAS score of the patients treated with RSWT was
reduced by 54.1% at 6-month follow-up but the total
mean VAS score of the patients treated with placebo only
by 3.9%. Marks et al. [9] concluded that there appeared to
be a profound placebo effect in patients with heel pain, as
well as a lack of evidence for the efficacy of RSWT in
treating PF compared to sham therapy.
The paper by Marks et al. [9] has some weaknesses:
(1) in the main text, the authors described an average
duration of heel pain of 28.3 months before RSWT or
sham treatment. On the other hand, the duration of
symptoms was reported in Table 1 of the same paper as
follows: 35.6 ± 43.2 days (mean ± standard deviation)
(range, 1 to 180 days) for the patients treated with
RSWT and 21.0 ± 16.4 days (range, 1 to 60 days) for the
patients treated with placebo. As was true in the trial by
Buchbinder et al. [29], Marks et al. [9] investigated mixed
groups of patients suffering from either acute or chronic
PF. Since more than 80% of PF patients experience reso-
lution within 12 months, regardless of management [1],
the approach by Marks et al. [9] could be considered an
inadequate selection of PF patients for RSWT rather than
reflecting inefficacy of RSWT treatment for this disease
(similar to the study by Buchbinder et al. [29] discussed
above). (2) This is further corroborated by the notion that
at least one patient treated with placebo had a VAS score
of 6 (with a maximum VAS score of 100) in the study by
Marks et al. [9], which would translate into a VAS score of
0.6 in the studies by Chow and Cheing [7], Gerdesmeyer
et al. [8], and Ibrahim et al. [11]. It remains unknown why
such almost pain-free patients were enrolled in the study
by Marks et al. [9].
Greve et al. [10] reported the results of 16 patients with
chronic PF treated with RSWT (three sessions each 7 days
apart, 2,000 impulses per session; EFD = 0.14 mJ/mm2,
six impulses per second, group A), and another n = 16
patients with chronic PF to conventional physiotherapy
(ten sessions of ultrasound, two sessions per week, plus
exercises, group B). The authors found that both treat-
ments were effective for pain reduction and improving the
functional abilities of patients with PF (treatment success
was not calculated as in the studies by Gerdesmeyer et al.
[8], Marks et al. [9], and Ibrahim et al. [11]). However, the
authors noted that the effects of RSWT occurred sooner
than physiotherapy after the onset of treatment.
In summary, the lack of treatment success in the study
by Marks et al. [9] using RSWT for PF can be explained
by serious methodological shortcomings in this study(as in the case of the studies by Haake et al. [26] and
Buchbinder et al. [29] on focused ESWT for chronic PF
discussed above). In contrast, the studies by Chow and
Cheing [7], Gerdesmeyer et al. [8], Greve et al. [10], and
Ibrahim et al. [11] demonstrated that chronic PF can be
treated successfully with RSWT. Most importantly, RSWT
for chronic PF was demonstrated to result in long-term
treatment success, demonstrated at both 6 [11] and
12 months [8] after the first treatment. These results
justify the general recommendation to offer RSWT to
patients 18 years of age or older with symptoms of PF
for 6 months or more and a history of unsuccessful
conservative therapy, before considering any surgical
treatment.ESWT/RSWT vs. surgery in the treatment of chronic
plantar fasciopathy
ESWT and RSWT have several advantages over surgery in
the treatment for chronic PF, including minimally invasive
percutaneous radio frequency nerve ablation propagated
recently [38-42]. Because RSWT does not require local
anesthesia, the procedure is completely non-invasive. In
contrast, surgery has risks such as transient swelling of
the heel pad, injury of the posterior tibial nerve or its
branches, and flattening of the longitudinal arch with
resultant midtarsal pain. In contrast to surgery, either
open or endoscopic, ESWT and RSWT do not require
patients to avoid weight bearing or a prolonged time for
return to work. Rather, ESWT and RSWT allow patients
to return to activities of daily life within 1 or 2 days,
with an immediate return to most jobs and normal daily
shoe wear.Conclusions
Both ESWT with focused shock waves and second
generation RSWT are safe, effective, and easy treatments
for chronic PF not responding to conservative therapy.
Efficacy and safety of both ESWT and RSWT for chronic
PF have been demonstrated in several RCTs in the inter-
national peer-reviewed literature. The lack of treatment
success in some published RCTs using ESWT or RSWT
can be explained by serious methodological shortcomings
in the corresponding studies rather than reflecting ineffi-
cacy of ESWT or RSWT for this disease. Unlike surgery,
ESWT and RSWT are non-invasive and can be performed
as in office procedures, without the use of anesthesia.
Furthermore, ESWT and RSWT do not require patients
to avoid weight bearing or a prolonged time for return
to work. The main advantages of RSWT over first
generation focused ESWT are the lack of need for any
anesthesia during the treatment and the demonstrated
long-term treatment success (demonstrated at both 6
and 12 months after the first treatment using RSWT,
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Appendix
This appendix addresses the question whether the pressure
waves generated with the Ossatron, Epos Ultra, Sonocur
Basic, Orbasone, and Orthospec devices fulfill the charac-
teristics set out by the following physical definition of
shock waves [15,16]: (1) a high positive peak pressure (P+),
sometimes more than 100 MPa but more often approxi-
mately 50 to 80 MPa, (2) a fast initial rise in pressure (Tr)
during a period of less than 10 ns, (3) a low tensile
amplitude (P−, up to 10 MPa), (4) a short life cycle (I) of
approximately 10 μs, and (5) a broad frequency spectrum,
typically in the range of 16 Hz to 20 MHz. This question
can be answered as follows: (1) the rise times of the pres-
sure waves generated with the Sonocur Basic and Orbasone
devices have not been published. Accordingly, it cannot be
decided whether the pressure waves generated with these
devices fulfill the characteristics set out by the physical
definition of shock waves provided above. (2) The pressure
waves generated with the Ossatron device were reported
to have a rise time of 38 ns and a maximum peak positive
pressure of 37.7 MPa [22,23]. Chitnis and Cleveland [22]
characterized these pressure waves as shock waves. (3)
The pressure waves generated with the Orthospec device
were reported to have a rise time of 400 ± 100 ns and a
maximum peak positive pressure of 34 ± 13 MPa [43].
Accordingly, the pressure waves generated with the
Orthospec device are not shock waves according to the
physical definition provided above. (4) Haake et al. [26]
and Buchbinder et al. [29] treated patients suffering
from PF with pressure waves generated with the Epos
Ultra device. Buchbinder et al. [29] used various energy
settings, i.e., within levels 1 to 9 (treatment began on level 1
and was gradually increased through to the highest
tolerable level of pain for each participant). In contrast,
Haake et al. [26] applied pressure waves with an EFD of
0.08 mJ/mm2 (i.e., level 3). The rise time of the pressure
waves generated with the Epos Ultra device is approxi-
mately 600 ns at level 1, approximately 500 ns at level 3,
approximately 200 ns at level 7, and less than 100 ns at
level 9 (EMS Electro Medical Systems, Nyon, Switzerland;Table 2 Characteristics of the pressure waves generated with
States
Wave characteristics Devices genera
Pressure waves that fulfill the characteristics set
out by the physical definition of shock waves belowa
Ossatron (SONOC
Pressure waves that do not fulfil the characteristics
set out by the physical definition of shock waves belowa
Orthosp
The names of the corresponding manufacturers are provided in the main text. aPhy
sometimes more than 100 MPa but more often approximately 50 to 80 MPa, (2) a f
tensile amplitude (P−, up to 10 MPa), (4) a short life cycle (I) of approximately 10 μs
20 MHz; brise time not published; cwhen operated at levels 1 to 7 (i.e., as in clinicalunpublished data). Furthermore, the positive peak pressure
of the pressure waves generated with the Epos Ultra device
is less than 7.5 MPa at level 1, less than 20 MPa at level 3,
approximately 36 MPa at level 7, and approximately
56 MPa at level 9 (EMS Electro Medical Systems, Nyon,
Switzerland; unpublished data). Accordingly, the pressure
waves generated with the Epos Ultra device applied by
Haake et al. [26] were not shock waves according to the
physical definition provided above. The same holds true
for the pressure waves generated with the Epos Ultra
device at levels 1 to 7 applied by Buchbinder et al. [29].
This is in line with Cleveland et al.’s [23] notion that for
treatment protocols at low energy settings, electromagnetic
ESWT devices (such as the Epos Ultra) will not produce
shock waves.
Accordingly, the pressure waves generated with the
Orthospec device, as well as the Epos Ultra device
operated at levels 1 to 7, do not fulfill the characteristics
set out by the physical definition of shock waves provided
above. Nevertheless, the pressure waves generated with
these devices are named shock waves in the international
peer-reviewed literature [26,28,29]. The same holds true
for the pressure waves generated with the Ossatron device
[22]. This indicates that in the field of musculoskeletal
applications of pressure waves, several definitions of shock
waves are used, irrespective of the type of generation or
focusing of these pressure waves. This is also illustrated by
the following characterization of shock waves applied to
the musculoskeletal system by Rompe et al. [5]: (1) rise
time < 1 μs and (2) positive peak pressure between 10 and
100 MPa (note that the pressure waves generated with the
Swiss DolorClast have a positive peak pressure of more
than 10 MPa when measured at 1 mm distance to the
applicator. Chitnis and Cleveland [22] and Cleveland et al.
[23] performed their measurements at 10 mm distance to
the applicator).
Thus, the difference between the Ossatron, Epos Ultra,
Sonocur Basic, Orbasone, and Orthospec devices on one
hand, and the Swiss DolorClast, on the other hand, is
not that the former devices produce shock waves and
the latter one does not. Rather, the former devices
generate focused pressure waves, whereas the latter
one produces unfocused pressure waves, and both arevarious ESWT/RSWT devices marketed in the United
ting focused shock waves Devices generating radial shock waves
UR Basic)b and (Orbasone)b
ec and Epos Ultrac Swiss DolorClast
sical definition of shock waves [15,16]: (1) a high positive peak pressure (P+),
ast initial rise in pressure (Tr) during a period of less than 10 ns, (3) a low
, and (5) a broad frequency spectrum, typically in the range of 16 Hz to
use for treatment of PF [26,29]).
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It is important to note that the usability of shock waves
for the treatment of the musculoskeletal system does not
depend on whether these waves are shock waves according
to the physical definition provided above or not. Rather, a
significant tissue effect of these shock waves is cavitation
consequent to the negative phase of the wave propagation
[15]. Specifically, Schelling et al. [44] demonstrated
stimulation of nerves with shock waves indirectly, i.e., via
a cavitation-mediated mechanism. Nerve stimulation is
nowadays hypothesized being a central mechanism of
action of ESWT/RSWT for the musculoskeletal system
[33-35]. As shown by Chitnis and Cleveland [22], both the
Ossatron device (generating focused shock waves that
fulfill the characteristics set out by the physical definition
of shock waves provided above) and the Swiss DolorClast
(generating radial shock waves that do not fulfill the char-
acteristics set out by the physical definition of shock waves
provided above) can induce cavitation (see also Figure 2).
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